Veradermics (MANE) EPS (Basic) (2025 - 2026)
Veradermics (MANE) posted EPS (Basic) of -$1.32 for Q1 2026, up 93.32% on a QoQ basis from -$19.79 in Q1 2025, and up 93.32% year-over-year from -$0.68 in Q1 2025.
Veradermics (MANE) EPS (Basic) (2025 - 2026) Analysis & Trends
Veradermics' EPS (Basic) history runs 2 years deep, the most recent figure standing at -$1.32 for Q1 2026.
- Quarterly EPS (Basic) rose 93.32% year-over-year to -$1.32 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.96 (changed N/A YoY) and the FY2025 annual result came in at -$111.91, down 202.06% from the prior year.
- EPS (Basic) was -$1.32 for Q1 2026 at Veradermics, up from -$19.79 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$1.32 in Q1 2026 and bottomed at -$19.79 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Veradermics | 2.51 Bn | 2.51 Bn | - | -1.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.32 |
| Mar 31, 2025 | -19.79 |